

# BEST AVAILABLE COPY

PTO/SB/81 (04-05)

Approved for use through 11/30/2005 OMB 0651-0035

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

## POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

Application Number	10/563550
Filing Date	2 July 2004
First Named Inventor	Andrew Patrick WILDENBERG
Title	Methods for detecting aneuploidy..
Art Unit	
Examiner Name	
Attorney Docket Number	007193-17US

I hereby revoke all previous powers of attorney given in the above-identified application.

I hereby appoint:

☒ Practitioners associated with the Customer Number

36234

OR

☐ Practitioner(s) named below.

Name	Registration Number

as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.

Please recognize or change the correspondence address for the above-identified application to:

☒ The address associated with the above-mentioned Customer Number:

OR

☐ The address associated with Customer Number.

OR

☐ Firm or Individual Name

Address

City

State

Zip

Country

Telephone

Email

I am the:

☐ Applicant/Inventor.

☒ Assignee of record of the entire interest. See 37 CFR 3.71.  
Statement under 37 CFR 3.73(b) is enclosed (Form PTO/SB/95)

GENERA BIOSYSTEMS PTY LTD SIGNATURE of Applicant or Assignee of Record

Signature	<i>Karl Poetter</i>	Date	June 8, 2006
Name	KARL POETTER	Telephone	613-9345-2251
Title and Company	Chief Scientific Officer, Genera Biosystems		

NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.

☐ \*Total of \_\_\_\_\_ forms are submitted.

This collection of information is required by 37 CFR 1.31, 1.32 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

# BEST AVAILABLE COPY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/98 (12-05)  
Approved for use through 07/31/2006. OMB 0551-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

## STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: GENERA BIOSYSTEMS PTY LTD

Application No./Patent No./Control No.: 10/583550 Filed/Issue Date: 2 July 2004

Entitled: METHODS FOR DETECTING ANEUPLOIDY USING MICROPARTICLE MULTIPLEX DETECTION

GENERA BIOSYSTEMS PTY LTD

(Name of Assignee)

a CORPORATION

(Type of Assignee: corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest; or
2. ☐ an assignee of less than the entire right, title and interest  
(The extent (by percentage) of its ownership interest is \_\_\_\_\_ %)

in the patent application/patent identified above by virtue of either:

A. ☐ An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel \_\_\_\_\_, Frame \_\_\_\_\_, or a true copy of the original assignment is attached.

OR

B. ☐ A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:

1. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
2. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.
3. From: \_\_\_\_\_ To: \_\_\_\_\_  
The document was recorded in the United States Patent and Trademark Office at  
Reel \_\_\_\_\_, Frame \_\_\_\_\_, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was, or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.

[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part 3, to record the assignment in the records of the USPTO. See MPEP 302.08]

The undersigned (whose title is supplied below) is authorized to act on behalf of the assignee.

*Karl Poetter*

Signature

KARL POETTER

Printed or Typed Name

Chief Scientific Officer

Title

June 8, 2006

Date

61-3-9345-2251

Telephone Number

This collection of information is required by 37 CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Applicant or Patentee: \_\_\_\_\_ Attorney's Dkt. No. 007193-17US  
Serial or Patent No.: \_\_\_\_\_  
Filed or Issued: \_\_\_\_\_  
For: \_\_\_\_\_

**VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL ENTITY  
STATUS [37 CFR 1.9 and 1.27(c)] - SMALL BUSINESS CONCERN**

I hereby declare that I am

- ☐ the owner of the small business concern identified below:  
☒ an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN GENERA BIOSYSTEMS PTY LTD

ADDRESS OF CONCERN Level 29, Riverside Centre, 123 Eagle St., Brisbane, QSL 4000

I hereby declare that the above identified small business concern qualifies as a small business concern as defined in 37 CFR 121.3-18, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees under section 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention, entitled:

**METHODS FOR DETECTING ANEUPLOIDY USING MICROPARTICLE MULTIPLEX DETECTION**

by inventors Andrew Patrick WILDENBERG and Karl POETTER described in

- ☐ the specification filed herewith. [X] International PCT/AU2004/000894  
☐ application Serial No. \_\_\_\_\_, filed \_\_\_\_\_  
☐ patent No. \_\_\_\_\_, issued \_\_\_\_\_

If the rights held by the above-identified small business concern are not exclusive, each individual, concern or organization having rights to the invention is listed below\* and no rights to the invention are held by any person, other than the inventor who could not qualify as an independent inventor under 37 CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d), or a nonprofit organization under 37 CFR 1.9(e). \*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities (37 CFR 1.27)

Name \_\_\_\_\_

Address \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

Name \_\_\_\_\_

Address \_\_\_\_\_

☐ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I acknowledge the duty to file, in this application of patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. [37 CFR 1.28(b)]

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing hereon, or any patent to which this verified statement is directed.

NAME OF PERSON SIGNING

TITLE OF PERSON OTHER THAN OWNER

ADDRESS OF PERSON SIGNING

SIGNATURE

Karl Poetter

Chief Scientific Officer

4 Research Ave, BUNDORA VIC AUSTRALIA

DATE May 30, 2006

**BEST AVAILABLE COPY**

**BEST AVAILABLE COPY**

US  
PATENT

Attorney's docket no. 007193-17US  
**ASSIGNMENT**

WHEREAS, I/WE

Andrew Patrick WILDENBERG, a United States citizen of 511 2<sup>nd</sup> Avenue South, Mount Vernon, Iowa 52403,  
United States;

Karl POETTER, a United States citizen of 25 Urquhart Street, Northcote, Victoria 3070, Australia

hereinafter referred to as Assignor (collectively if more than one inventor is listed above), have invented certain new and useful improvements in  
**Methods for detecting aneuploidy using microparticle multiplex detection**

the specification of which:

- (a) ☐ was executed on even date herewith;  
(b) ☐ was filed on \_\_\_\_\_ as ☐ Application No \_\_\_\_\_ or  
☐ Express Mail No., as Application No. not yet known \_\_\_\_\_ and was amended on  
\_\_\_\_\_(if applicable); or  
(c) ☒ was described and claimed in PCT International Application PCT/AU2005/000894  
filed on 2 July 2004 and as amended under PCT Article 19 on \_\_\_\_\_ (if any) and/or under  
PCT Article 34 on 24 March 2005 & 4 October 2005 (if any).

AND WHEREAS,

GENERA BIOSYSTEMS PTY LTD, of Level 29, Riverside Centre, 123 Eagle Street, Brisbane, Queensland 4000,  
Australia


(hereinafter referred to as Assignee) desires to acquire the entire rights, title, and interest in and to the said improvements with respect to the  
United States of America, its territories and possessions.

NOW, THEREFOR, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby acknowledges that it has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, the entire right, title, and interest in the United States of America, and its territories and possessions in, to and under said improvements, and any Patent Applications in the United States of America and all divisions, renewals and continuations thereof, and all Patents of the United States of America which may be granted thereon and all reissues and extensions thereof, and all rights of priority under International Conventions; and Assignor hereby authorizes and requests the Commissioner of Patents of the United States of America to issue all Patents for said improvements to Assignee, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR HEREBY covenants and agrees that it will communicate to Assignee, its successors, legal representatives and assigns, any facts known to it respecting said improvements, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for said improvements in the United States of America.

IN TESTIMONY WHEREOF, Assignor intending to be legally bound has hereunto affixed its signature.

This 6<sup>th</sup> day of June, 2006

  
Signature of Andrew Patrick WILDENBERG

  
Witness

This \_\_\_\_\_ day of \_\_\_\_\_, 20

Signature of Karl POETTER

Witness

**BEST AVAILABLE COPY**

US  
PATENT

Attorney's docket no. 007193-17US  
**ASSIGNMENT**

WHEREAS, I/WE

**Andrew Patrick WILDENBERG**, a United States citizen of 511 2<sup>nd</sup> Avenue South, Mount Vernon, Iowa 52403, United States;

**Karl POETTER**, a United States citizen of 25 Urquhart Street, Northcote, Victoria 3070, Australia

hereinafter referred to as Assignor (collectively if more than one inventor is listed above), have invented certain new and useful improvements in  
**Methods for detecting aneuploidy using microparticle multiplex detection**

the specification of which:

- (a) ☐ was executed on even date herewith;
- (b) ☐ was filed on \_\_\_\_\_ as ☐ Application No. \_\_\_\_\_ or  
☐ Express Mail No., as Application No. not yet known \_\_\_\_\_ and was amended on  
\_\_\_\_\_ (if applicable); or
- (c) ☒ was described and claimed in PCT International Application PCT/AU2005/000894  
filed on 2 July 2004 and as amended under PCT Article 19 on \_\_\_\_\_ (if any) and/or under  
PCT Article 34 on 24 March 2005 & 4 October 2005 (if any).

AND WHEREAS,

**GENERA BIOSYSTEMS PTY LTD**, of Level 29, Riverside Centre, 123 Eagle Street, Brisbane, Queensland 4000, Australia

(hereinafter referred to as Assignee) desires to acquire the entire rights, title, and interest in and to the said improvements with respect to the United States of America, its territories and possessions.

NOW, THEREFOR, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, Assignor hereby acknowledges that it has sold, assigned, transferred and set over, and by these presents does hereby sell, assign, transfer and set over, unto Assignee, its successors, legal representatives and assigns, the entire right, title, and interest in the United States of America, and its territories and possessions in, to and under said improvements, and any Patent Applications in the United States of America and all divisions, renewals and continuations thereof, and all Patents of the United States of America which may be granted thereon and all reissues and extensions thereof, and all rights of priority under International Conventions; and Assignor hereby authorizes and requests the Commissioner of Patents of the United States of America to issue all Patents for said improvements to Assignee, its successors, legal representatives and assigns, in accordance with the terms of this instrument.

AND ASSIGNOR HEREBY covenants and agrees that it will communicate to Assignee, its successors, legal representatives and assigns, any facts known to it respecting said improvements, and testify in any legal proceeding, sign all lawful papers, execute all divisional, continuing and reissue applications, make all rightful oaths and generally do everything possible to aid Assignee, its successors, legal representatives and assigns, to obtain and enforce proper patent protection for said improvements in the United States of America.

IN TESTIMONY WHEREOF, Assignor intending to be legally bound has hereunto affixed its signature.

This \_\_\_\_\_ day of \_\_\_\_\_, 20

\_\_\_\_\_  
Signature of **Andrew Patrick WILDENBERG**

\_\_\_\_\_  
Witness

This 8 day of June, 2006

  
\_\_\_\_\_  
Signature of **Karl POETTER**

  
\_\_\_\_\_  
Witness